Patent ID: 6509363
Filing Date: 2003-01-21
Classification: A61P,C07D

Abstract:
A compound having the formula: wherein: each of Q1 and Q2 is independently selected from the group consisting of a 5-6 membered aromatic carbocyclic or heterocyclic ring system, and an 8-10 membered bicyclic ring system comprising aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring; or wherein: Q1 is selected from the group consisting of a 5-6 membered aromatic carbocyclic or heterocyclic ring systam and an 8-10 membered bicyclic ring system comprising aromatic carbocyclic rings, aromatic heterocyclic rings or a combination of an aromatic carbocyclic ring and an aromatic heterocyclic ring, and Q2 is selected from the group consisting of H, CO2Râ€², CON(Râ€²)2, and a (C1-C4) branched or straight-chain alkyl optionally containing 1-3 substituents independently selected from the group consisting of A, Tâ€”C(O)Râ€², OPO3H2,NRâ€²2,ORâ€²,CO2Râ€²,CON(Râ€²)2, and SO2N(R2)2; wherein: Q1 is optionally substituted with 1 to 4 substituents, each of which is independently selected from the group consisting of halo; C1-C4 alkyl optionally containing 1-3 substituents independently selected from the group consisting of A, Tâ€”C(O)Râ€²,OPO3H2, NRâ€²2,ORâ€²,CO2Râ€² and CONRâ€²2;Oâ€”(C1-C4)-alkyl optionally containing 1-3 substituents independently selected from the group consisting of A,Tâ€”C(O)Râ€²,OPO3H2,NRâ€²2,ORâ€², CO2Râ€² and CONRâ€²2;NRâ€²2;OCF3;CF3;NO2;CO2Râ€²;CONRâ€²;SRâ€²;S(O2)N(Râ€²)2;SCF3; CN;N(Râ€²)C(O)R4;N(Râ€²)C(O)OR4;N(Râ€²)C(O)C(O)R4;N(Râ€²)S(O2)R4;N(Râ€²)R4;N(R4)2; OR4;OC(O)R4;OP(O)3H2; and N&boxH;Câ€”N(Râ€²)2; and wherein: Q2, when a ring system, is optionally substituted with up to 4 substituents, each of which is independently selected from the group consisting of halo; C1-C4 straight or branched alkyl optionally containing 1-3 substituents independently selectd from the group consisting of A, Tâ€”C(O)Râ€²,OPO3H2,NRâ€²2,ORâ€²,CO2Râ€²,S(O2)N(Râ€²)2,N&boxH;Câ€”N(Râ€²)2,R3, and CONRâ€²2;Oâ€”(C1-C3)-alkyl; Oâ€”(c1-C4)-alkyl optionally containing 1-3 substituents independently selected from the group consisting of A, Tâ€”C(O)Râ€²,OPO3H2,NRâ€²2,ORâ€², CO2Râ€², S(O2)N(Râ€²)2, N=Câˆ’N(Râ€²)2, R3, and CONRâ€²2; OCF3; CF3, NO2; CO2Râ€²; CONRâ€²;R3;OR3;NR3;SR3;C(O)R3;C(O)N(Râ€²)R3;C(O)OR3;SRâ€²;S(O2)N(Râ€²)2;SCF3; N&boxH;Câ€”N(Râ€²)2; and CN; wherein A is selected from the group consisting of; wherein Râ€² is selected from the group consisting of hydrogen, (C1-C3)-alkyl; (C2-C3)-alkenyl or alkynyl; and phenyl or phenyl substituted with 1 to 3 substituents independently selected from the group consisting of halo, methoxy, cyano, nitro, amino, hydroxy, methyl and ethyl;wherein R3 is a 5-6 membered aromatic carbocyclic or heterocyclic ring system; wherein R4 is (C1-C4)-alkyl optionally substituted with N(Râ€²)2,ORâ€²,CO2Râ€², CON(Râ€²)2, or SO2N(R2)2; a 5-6 membered carbocyclic or heterocyclic ring system optionally substituted with a (C1-C4) branched or straight-chain alkyl group, N(Râ€²)2,ORâ€², CO2Râ€²,CON(Râ€²)2, or SO2N(R2)2; or a (C1-C4)-alkyl optionally substituted with the 5-6 membered carbocyclic or heterocyclic ring system optionally substituted with a (C1-C4) branched or straight-chain alkyl group, N(Râ€²)2,ORâ€²,CO2Râ€²,CON(Râ€²)2, or SO2N(R2)2; wherein R2 is selected from the group consisting of hydrogen, (C1-C3)-alkyl, and (C1-C3)-alkenyl; each optionally substituted with â€”N(Râ€²)2, â€”ORâ€², SRâ€², â€”C(O)â€”N(Râ€²)2,â€”S(O2)â€”N(Râ€²)2,â€”C(O)â€”ORâ€², or R3; wherein X is selected from the group consisting of O,S,NR and C(R)2; wherein Y is CR or N; wherein Z is CH or N; wherein M is C&boxH;O,CHOH, or CH2; wherein n is 0 or 1; wherein each R is independently selected from the group consisting of hydrogen â€”R2,â€”N(R2)2,â€”OR2,SR2,â€”C(O)â€”N(R2)2,â€”S(O2)â€”N(R2)2, and â€”C(O)â€”OR2, wherein two adjacent R are optionally bound to one another and, together with each Y to which they are respectively bound, form a 4-8 membered carbocyclic or heterocyclic ring; and pharmaceutically acceptable salts thereof; wherein when Q1 is substituted with 1 to 3 substituents, Q2 is a ring system, X is NR or C(R)2, and n is 1, then M is not â€”C(O)â€” or â€”CH2â€”; when Y is N and/or X is NR, Z is CH, n is 0 and Q1 is a substituted or unsubstituted phenyl or thienyl group, then Q2 is not H; and when Y is CH, X is S, Z is CH, and n is 0, then Q2 is not H.